Researchers at the University of Colorado Anschutz Medical Campus have successfully developed an iteration of CAR-T cell ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

Scientists may have unlocked a new milestone in cancer treatment. An individual who received CAR T-cell therapy has been in ...

The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.

Investigators detected low levels of CAR T cells persisting in patients during the follow-up observation period, with higher persistence detected in long-term survivors. The first-generation CAR T ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

A handful of biotechs are asking a next-generation question ... body [to make] literal homeostatic space for the incoming CAR-T cells,” Kevin Friedman, CEO of Kelonia Therapeutics, told ...

The "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...